First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.

Key facts

Study ID

NCT01529307

Run by

Novartis Pharmaceuticals

People needed

6

Starts

2012-06-01

Expected to finish

2012-09-01

Last updated by the study team

2020-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of solid tumors
• 18 years or older
• ECOG performance status of 0, 1 or 2
• Adequate bone marrow, hepatic and renal function
• Obtained written informed consent

You may not qualify if…

• Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS metastases may be allowed if certain conditions are met.
• Major surgery within 4 weeks before study treatment
• Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations
• Impaired cardiac functions
• Previous hepatitis viral infection such as hepatitis B or hepatitis C
• Diagnosis of HIV infection
• Pregnant or nursing (lactating) women
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC — Tampa, Florida, United States
• South Texas Accelerated Research Therapeutics START — San Antonio, Texas, United States
• University of Utah / Huntsman Cancer Institute Huntsman UT — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.